Information  X 
Enter a valid email address

Company Name matching 'Biogen Inc.'

Date
Time Source
Company
Announcement
29 Jul 2021 9:10 pm GNW   Biogen Inc. Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
26 Jul 2021 9:10 pm GNW   Biogen Inc. Biogen and Eisai Announce ADUHELM™(aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
23 Jul 2021 9:30 pm GNW   Biogen Inc. Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference
22 Jul 2021 12:05 pm GNW   Biogen Inc. An open letter to the Alzheimer’s disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.
13 Jul 2021 12:00 am GNW   Biogen Inc.; InnoCare Pharma L Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
08 Jul 2021 9:06 pm GNW   Biogen Inc. Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
  12:30 pm GNW   Biogen Inc. FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
25 Jun 2021 12:30 pm GNW   Biogen Inc. Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™
17 Jun 2021 12:30 pm GNW   Biogen Inc. Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
16 Jun 2021 9:30 pm GNW   Biogen Inc. Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease
15 Jun 2021 11:30 am GNW   Biogen Inc. Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
14 Jun 2021 9:06 pm GNW   Biogen Inc. Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia
10 Jun 2021 12:30 pm GNW   Biogen Inc. New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
07 Jun 2021 6:01 pm GNW   Biogen Inc. Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
  6:00 pm GNW   Biogen Inc. FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
01 Jun 2021 12:30 pm GNW   Biogen Inc. Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)
21 May 2021 12:30 pm GNW   Biogen Inc. Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
20 May 2021 9:06 pm GNW   Biogen Inc. Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland
14 May 2021 12:30 pm GNW   Biogen Inc. Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP
13 May 2021 9:06 pm GNW   Biogen Inc.; Envisagenics Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
12 May 2021 12:30 pm GNW   Biogen Inc. Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data
10 May 2021 9:06 pm GNW   Biogen Inc. Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders
28 Apr 2021 11:20 pm GNW   Biogen Inc. Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)
  12:30 pm GNW   Biogen Inc. Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
19 Apr 2021 12:30 pm GNW   Biogen Inc. Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
16 Apr 2021 12:30 pm GNW   Biogen Inc. New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis
15 Apr 2021 9:30 pm GNW   Biogen Inc. Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis
14 Apr 2021 9:06 pm GNW   Biogen Inc. Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021
09 Apr 2021 9:30 pm GNW   Biogen Inc. Biogen Announces Two New Nominees for Election to Board of Directors
08 Apr 2021 12:00 pm GNW   Biogen Inc. Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis
07 Apr 2021 12:30 pm GNW   Biogen Inc. The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis
04 Mar 2021 12:47 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina
24 Feb 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
11 Feb 2021 1:03 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces the Expiration Date Results of Its Cash Tender Offer
  1:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces the Expiration Date Results of Its Private Exchange Offer
10 Feb 2021 6:02 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces the Pricing Terms of its Cash Tender Offer
  6:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces the Pricing Terms of Its Private Exchange Offer
04 Feb 2021 2:02 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
  2:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors
01 Feb 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
29 Jan 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
11 Jan 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
08 Jan 2021 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
21 Dec 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
10 Dec 2020 3:30 am GNW Factsheet Biogen Inc. (0R1B) Biogen Files New Drug Application for Aducanumab in Japan
27 Nov 2020 12:30 pm GNW Factsheet Biogen Inc.; Sage Therapeutics (0R1B) Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
18 Nov 2020 12:00 pm GNW Factsheet Biogen Inc. (0R1B) Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
16 Nov 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership
07 Nov 2020 1:15 am GNW Factsheet Biogen Inc. (0R1B) Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
03 Nov 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
30 Oct 2020 11:00 am GNW Factsheet Biogen Inc. (0R1B) European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
06 Oct 2020 12:00 pm GNW Factsheet Biogen Inc.; Samsung Bioepis (0R1B) Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
14 Sep 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health
11 Sep 2020 1:01 pm GNW Factsheet Biogen Inc. (0R1B) New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio
08 Sep 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
07 Aug 2020 12:30 pm GNW Factsheet Biogen Inc. (0R1B) FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
06 Aug 2020 1:02 pm GNW Factsheet Biogen Inc.; Denali Therapeuti (0R1B) Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
24 Jul 2020 9:06 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease
21 Jul 2020 11:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
  12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t